Pages that link to "Q38202636"
Jump to navigation
Jump to search
The following pages link to Pharmacology and clinical efficacy of dimethyl fumarate (BG-12) for treatment of relapsing-remitting multiple sclerosis (Q38202636):
Displaying 10 items.
- Is Modulation of Oxidative Stress an Answer? The State of the Art of Redox Therapeutic Actions in Neurodegenerative Diseases (Q26765787) (← links)
- A generalizable platform for interrogating target- and signal-specific consequences of electrophilic modifications in redox-dependent cell signaling (Q28385286) (← links)
- Nrf2-dysregulation correlates with reduced synthesis and low glutathione levels in experimental autoimmune encephalomyelitis (Q28394597) (← links)
- The antipsoriatic agent monomethylfumarate has antiproliferative, prodifferentiative, and anti-inflammatory effects on keratinocytes. (Q34785582) (← links)
- Distinct Nrf2 Signaling Mechanisms of Fumaric Acid Esters and Their Role in Neuroprotection against 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine-Induced Experimental Parkinson's-Like Disease (Q36985371) (← links)
- Dimethyl fumarate may still have a role in progressive multiple sclerosis. (Q37027689) (← links)
- Repurposing the NRF2 Activator Dimethyl Fumarate as Therapy Against Synucleinopathy in Parkinson's Disease (Q37091371) (← links)
- Effect of dimethyl fumarate on renal disease progression in a genetic ortholog of nephronophthisis (Q50046953) (← links)
- Efficacy of dimethyl fumarate in Japanese multiple sclerosis patients: interim analysis of randomized, double-blind APEX study and its open-label extension (Q92486205) (← links)
- Antibody signatures in patients with histopathologically defined multiple sclerosis patterns (Q92719818) (← links)